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Identification of a pituitary ERα-activated 
enhancer triggering the expression of Nr5a1, 
the earliest gonadotrope lineage-specific 
transcription factor
Vincent Pacini, Florence Petit, Bruno Querat, Jean‑Noël Laverriere, Joëlle Cohen‑Tannoudji and David L’hôte* 
Abstract 
Background: Gonadotrope lineage differentiation is a stepwise process taking place during pituitary development. 
The early step of gonadotrope lineage specification is characterized by the expression of the Nr5a1 transcription fac‑
tor, a crucial factor for gonadotrope cell fate determination. Abnormalities affecting Nr5a1 expression lead to hypo‑
gonadotropic hypogonadism and infertility. Although significant knowledge has been gained on the signaling and 
transcriptional events controlling gonadotrope differentiation, epigenetic mechanisms regulating Nr5a1 expression 
during early gonadotrope lineage specification are still poorly understood.
Results: Using ATAC chromatin accessibility analyses on three cell lines recapitulating gradual stages of gonadotrope 
differentiation and in vivo on developing pituitaries, we demonstrate that a yet undescribed enhancer is transiently 
recruited during gonadotrope specification. Using CRISPR/Cas9, we show that this enhancer is mandatory for the 
emergence of Nr5a1 during gonadotrope specification. Furthermore, we identify a highly conserved estrogen‑bind‑
ing element and demonstrate that the enhancer activation is dependent upon estrogen acting through ERα. Lastly, 
we provide evidence that binding of ERα is crucial for chromatin remodeling of Nr5a1 enhancer and promoter, lead‑
ing to RNA polymerase recruitment and transcription.
Conclusion: This study identifies the earliest regulatory sequence involved in gonadotrope lineage specification and 
highlights the key epigenetic role played by ERα in this differentiation process.
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Background
Nr5a1 gene (also called Sf-1 or Ad4BP) is a transcription 
factor (TF) belonging to the nuclear receptor superfamily. 
In mammals, Nr5a1 is expressed notably in testes, adre-
nal glands, ventromedial hypothalamic nucleus (VMH) 
and anterior pituitary gland where it participates in 
embryonic cell differentiation and adult function [1]. The 
anterior pituitary is composed of six hormone-secreting 
cell types, i.e., corticotrope, melanotrope, somatotrope, 
lactotrope, thyrotrope and gonadotrope cells, originating 
from common precursor stem cells of the Rathke’s pouch 
[2]. Several TFs are known to promote pituitary stem 
cells differentiation into a specific endocrine lineage: 
POU1F1 is mandatory for the thyrotrope, somatotrope 
and lactotrope lineages [3], TBX19 for the corticotrope 
[4], PAX7 for the melanotrope [5] and Nr5a1 for the gon-
adotrope lineage [6]. During gonadotrope cells specifica-
tion, Nr5a1 is the earliest specific marker gene known to 
be expressed [6] initiating transcription of key genes such 
as Gnrhr (GnRH receptor gene) and Lhb (β-subunit of 
the gonadotropin LH gene). As a consequence, mutations 
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in the human Nr5a1 gene [7] and Nr5a1 knockout in 
mice lead to gonadotrope deficiency [6].
Nr5a1 expression depends on tissue-specific cis-regu-
latory elements. Two main promoters, 1A and 1G, have 
been characterized. The 1G promoter is the predomi-
nantly activated promoter in the pituitary [8]. However, it 
is not able, alone, to initiate Nr5a1 expression [9]. Addi-
tional distal enhancers are required for tissue-specific 
transcription. Four specific enhancers have been identi-
fied that control expression of Nr5a1 in the VMH [10], 
fetal adrenal glands [11], fetal Leydig cells [12] or gon-
adotrope cells [13]. The gonadotrope enhancer has been 
suggested to be implicated in Nr5a1 expression in gonad-
otropes from mouse embryonic day 13.5 (E13.5) onwards 
[13]. In a previous work [14], we characterized the epige-
netic marks decorating cis-regulatory regions of Nr5a1. 
We used a set of three cell lines recapitulating three stages 
of gonadotrope differentiation. The αT1–1 cells are likely 
derived from E12.5 common precursor cells from which 
originate thyrotrope and gonadotrope lineages. These 
cells do not express Nr5a1 yet. The αT3–1 cells are likely 
derived from cells engaged in a gonadotrope cell fate at 
E13.5 and express some of the gonadotrope-specific 
genes including Nr5a1. The LβT2 cells are likely derived 
from mature gonadotrope cells and express all the known 
marker genes [15–17]. We observed that although Nr5a1 
is already expressed in αT3–1 cells, the epigenetic marks 
on the gonadotrope enhancer indicate that it is repressed, 
suggesting that it does not regulate Nr5a1 expression at 
early steps of gonadotrope specification.
In this work, using functional genomic in  vitro and 
in vivo approaches, we demonstrated that Nr5a1 expres-
sion is triggered by another early activated enhancer 
at the emergence of gonadotrope lineage. We showed 
that this enhancer is activated by the estrogen pathway 
through ERα leading to P300 histone acetyltransferase 
recruitment. We also demonstrated that ERα protects 
the enhancer from inhibition by DNA methylation and 
chromatin compaction. Finally, we showed that the 
enhancer interacts with the Nr5a1 pituitary promoter 
and increases histone acetylation, RNA polymerase 
recruitment and Nr5a1 transcription. Activation of this 
enhancer is thus the earliest known mechanism impli-
cated in gonadotrope cell specification.
Results
Differential chromatin accessibility in Nr5a1 locus 
during gonadotrope specification
We performed an assay for transposase-accessible chro-
matin with high-throughput sequencing analysis (ATAC-
seq) in αT1–1, αT3–1 and LβT2 cell lines, allowing the 
identification of new potential cis-regulatory sequences 
(Fig.  1a and Additional file  1). We observed massive 
changes in chromatin accessibility in the three cell lines 
with about 20,000 specific accessible regions per line. 
Genomic regions associated with genes known to be 
expressed in the three cell lines, such as Cga or Isl1 pro-
moters, were open in all cell lines. Regions associated 
with Gnrhr promoter were accessible in both αT3–1 and 
LβT2, whereas those associated with Lhb promoter were 
only found in LβT2 cells (Additional file  1). Chromatin 
accessibility is thus consistent with the maturation stage 
of these cellular models.
We then analyzed chromatin accessibility of the Nr5a1 
locus. In αT1–1, consistent with the absence of Nr5a1 
expression, very few genomic regions were accessible 
in the Nr5a1 locus. In αT3–1, several open chroma-
tin regions could be observed and among them two had 
already been described: the 1G promoter, in agreement 
with Nr5a1 expression and, more surprisingly, the fetal 
Leydig enhancer (FL enhancer). This enhancer has been 
formerly described to be active specifically in the fetal 
testis [12]. The gonadotrope enhancer (named hereafter 
β enhancer) showed only very limited chromatin acces-
sibility in αT3–1 cells, in agreement with our previous 
observations [14]. The chromatin was also accessible for 
a previously undescribed region encompassing two very 
close peaks in intron 4 (peak-1: mm9 chr2:38,559,896–
38,560,286 and peak-2: mm9 chr2:38,562,187–
38,562,583), named hereafter the α region. This region 
exhibited only limited chromatin accessibility in αT1–1 
cells. In LβT2 cells, the 1G promoter as well as the FL and 
β enhancers all showed accessible chromatin conforma-
tion. In contrast, the chromatin of the α region was no 
more accessible.
These results strongly suggested that the Nr5a1 locus 
displays dynamic chromatin accessibility during gon-
adotrope lineage differentiation. In order to investigate 
whether the same dynamics could be observed in  vivo, 
we set up an ATAC assay followed by qPCR on develop-
ing pituitaries of mouse embryos (Fig. 1b). We observed 
that the 1G promoter was significantly open at E13.5 and 
E14.5 compared to E12.5, in agreement with the Nr5a1 
expression dynamics during mouse pituitary develop-
ment [6]. Chromatin at the α region was strongly and 
transiently accessible at E13.5. While chromatin at the β 
enhancer displayed a very limited accessibility at E13.5, 
it was fully open at E14.5. Finally, the FL enhancer was 
open from E13.5 onwards. Differential chromatin acces-
sibility in Nr5a1 locus during gonadotrope specification 
was thus validated in developing embryos in vivo.
Discovery of an undescribed early enhancer in Nr5a1 locus
In order to further characterize regions with chromatin 
accessibility, we studied in the three cell lines the depo-
sition of H3K4me3, H3K4me1 and H3K27ac histone 
Page 3 of 17Pacini et al. Epigenetics & Chromatin           (2019) 12:48 
marks, specific for promoters, enhancers and active ele-
ments, respectively (Fig.  2a–c). Only the 1G promoter 
was significantly enriched with H3K4me3 in αT3–1 and 
LβT2 cells (Fig.  2a). All other regions had significant 
H3K4me1 enrichment at these three stages of gonado-
trope maturation, indicating that they all are potential 
Fig. 1 Differential chromatin accessibility in the Nr5a1 locus during gonadotrope specification. a The Nr5a1 locus displays differential local 
chromatin accessibility depending on gonadotrope differentiation stage in vitro. Chromatin accessibility was investigated by assay for 
transposase‑accessible chromatin with high‑throughput sequencing (ATAC‑seq) in αT1–1, αT3–1 and LβT2 gonadotrope cell lines. ATAC‑seq 
tracks are shown for 45 Kb of the Nr5a1 locus. Accessible chromatin regions identified from ATAC‑seq results are shown for each cell line under 
each track (respectively, in gray, blue and yellow). In the last lane are summarized in black the potential regulatory regions, based on accessible 
chromatin sequences identified in at least one cell line. b Nr5a1 potential regulatory regions show differential chromatin accessibility depending 
on gonadotrope differentiation stage in vivo. ATAC assay followed by real‑time PCR quantification (ATAC‑qPCR) was performed on pituitary cells 
dispersed from developing glands of E12.5, E13.5 and E14.5 mouse embryos. Quantitative PCR was performed using sets of primers targeting 
the potential cis‑regulatory regions. Raw qPCR data were normalized to control region (see “Materials and Methods”) and to E12.5 stage of 
development. At this stage, Nr5a1 gene is not expressed and the locus is expected to be in a closed chromatin conformation. Results are the 
mean ± SEM of three independent experiments. Change in chromatin accessibility between E12.5 and E13.5 or E12.5 and E14.5 embryonic stages is 
compared using a Mann–Whitney test. Significant difference with E12.5 stage: “a” p < 0.05; “b” p < 0.01; “c” p < 0.001
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enhancers (Fig.  2b). Concerning deposition of the 
active chromatin mark (Fig.  2c), the 1G promoter and 
FL enhancer were enriched in H3K27ac only in αT3–1 
and LβT2 cells. While the β enhancer was decorated 
with H3K27ac only in LβT2, the α potential enhancer 
was significantly decorated with H3K27ac in αT1–1 
and αT3–1 cells (Fig.  2c, fold enrichment of 2.6 ± 0.4, 
p < 0.05 and 8.4 ± 1.0, p < 0.01, respectively).
Potential cis-regulatory activity was then studied 
in luciferase reporter system (Fig.  2d). We observed 
that the FL enhancer and 1G promoter were active in 
the three cell lines. A significant cis-regulatory activ-
ity of the α enhancer peak-2 could be already observed 
in αT1–1 that was strongly increased in αT3–1 (fold 
induction of 5.6 ± 0.8 and 38.5 ± 1.4 over control Pluc–
Prl, p < 0.01 in αT1–1 and αT3–1, respectively) but lost 
in LβT2 cells. As peak-1 did not show any regulatory 
activity in the αT3–1 cell line (Additional file 2A), sub-
sequent experiments were performed on the peak-2 
only and α enhancer will thereafter refer to this peak. 
The β enhancer displayed a significant cis-regulatory 
activity only in LβT2 cells (fold induction of 3.8 ± 0.2, 
p < 0.01). Altogether these results suggest that: (i) the 
β enhancer is active only during the terminal matura-
tion stage; (ii) the FL enhancer might also be recruited 
Fig. 2 Discovery of an undescribed early enhancer of Nr5a1 gene. 
a, b and c Nr5a1‑accessible chromatin regions harbor differential 
epigenetic marks of active enhancers depending on gonadotrope 
stage of differentiation. Epigenetic modifications of histone H3 
associated with ATAC‑seq open regions were investigated using 
chromatin immunoprecipitation assays in αT1–1, αT3–1 and LβT2 
cell lines. Analyzed marks were lysine 4 tri‑ and monomethylation 
H3K4me3 (a) and H4K4me1 (b), specific of promoters and enhancers, 
respectively, and lysine 27 acetylation H3K27ac (c), enriched on active 
cis‑regulatory sequences. Quantitative PCR was performed using sets 
of primers targeting ATAC‑seq open regions. Raw qPCR data were 
normalized to input. The final results were expressed as fold over the 
control region. ANOVA followed by Dunnett’s multiple comparison 
tests was performed independently for each cell line and each 
histone modification. Results are the mean ± SEM of six independent 
experiments. Significant difference with the control region: “a” p < 0.05; 
“b” p < 0.01. d Nr5a1‑accessible chromatin regions display differential 
cis‑regulatory activity depending on gonadotrope differentiation 
stage. αT1–1, αT3–1 and LβT2 cells were transiently transfected with 
the potential cis‑regulatory regions cloned in a pGL3b luciferase 
reporter system containing a minimal prolactin promoter (Pluc–Prl). 
Relative luciferase activity was measured as indicated in “Materials 
and Methods.” ANOVA followed by Dunnett’s multiple comparison 
tests was performed independently for each cell line. Results are 
normalized to control Pluc–Prl plasmid and are the mean ± SEM of 
six independent experiments. Significant difference with the control 
construct: “a” p < 0.05; “b” p < 0.01
▸
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in gonadotropes; (iii) the α region is a genuine gonado-
trope enhancer potentially activated in precursor and 
immature cells.
The α enhancer regulates Nr5a1 expression specifically 
in immature gonadotropes
CpGs DNA methylation of the active enhancers was 
investigated by bisulfite DNA sequencing. As shown in 
Fig. 3a, CpGs of the α enhancer were mostly hypermeth-
ylated in progenitors, fully demethylated in immature and 
methylated again in mature cells. The FL enhancer was 
hypermethylated in αT1–1 and unmethylated in αT3–1 
and LβT2 cells. Thus, both DNA methylation and histone 
decoration show that the FL enhancer is totally inactive 
in progenitors and active in immature and mature cells. 
In contrast, the α enhancer is in a bivalent state in pro-
genitors, exhibiting both active and inactive marks, active 
in immature and totally silent in mature gonadotropes.
To further confirm the regulatory role of the α 
enhancer in Nr5a1 expression, the peak-2 genomic 
sequence was excised from αT3–1 genome by CRISPR/
Cas9. Excision was also performed for the FL enhancer. 
Deletion of the FL enhancer did not alter Nr5a1 expres-
sion in αT3–1, whereas deletion of α enhancer sequence 
led to a strong reduction in expression as revealed by a 
85% decrease in Nr5a1 mRNA level (Fig.  3b, p < 0.001). 
This drastic reduction was observed in three independent 
clones for two independent gRNA couples, ruling 
out potential gRNA off target effects. (The genomic 
sequences of deleted clones along with gRNAs position 
are shown in Additional file  2B.) In order to inactivate 
this enhancer without altering the DNA sequence, we 
targeted dCas9–LSD1, a lysine-specific histone dem-
ethylase to the α enhancer. In αT3–1 cells, this led to an 
80% decrease in Nr5a1 mRNA level as compared with 
control gRNA (Fig. 3c, p < 0.01). Decommissioning the α 
enhancer in LβT2 cells did not impair Nr5a1 expression, 
while targeting LSD1 to the β enhancer strongly reduced 
it (fold decrease of about 90%, Additional file  3A). The 
transient α enhancer activation is thus mandatory for 
Nr5a1 expression specifically in immature gonadotropes. 
Chromatin interaction between the α enhancer and 1G 
promoter was investigated in αT1–1 and αT3–1 using 
quantitative chromatin conformation capture (3C) assay 
(Fig. 3d). We also tested potential interactions with con-
trol regions, external (Ce) and internal (Ci) to the Nr5a1 
locus as well as the FL enhancer. No interaction between 
the α enhancer and the upstream region (Ce/α) could 
be detected in the two cell lines. In contrast, in αT3–1 
cells (and to a lesser extent in the αT1–1), the α enhancer 
interacts significantly with the 1G promoter as well as 
with the FL enhancer (Fig. 3d).
Fig. 3 The α enhancer regulates Nr5a1 expression specifically in immature gonadotropes. a The α enhancer exhibits different DNA CpG 
methylation status according to gonadotrope differentiation stage. Genomic DNA of αT1–1, αT3–1 and LβT2 cells was extracted and bisulfited. 
The FL enhancer and α enhancer‑bisulfited sequences were amplified and cloned. A minimum of five clones per cell line was sequenced. Top: 
Schematic representation of enhancer sequences with location of CpGs (open‑circle lollipops). Numbering is relative to Nr5a1 1A promoter TSS. 
The state of CpG methylation for each cell line, methylated (black circles) or unmethylated (open circles), is indicated below. b The regulation of 
Nr5a1 expression is dependent on the α enhancer sequence in immature αT3–1 cells. Deletion of genomic sequence of the FL and α enhancers 
was carried out in αT3–1 cells using CRISPR/Cas9 and two independent specific guide RNA (gRNA) couples flanking each enhancer sequence: α 
gRNA1–gRNA3 or α gRNA2–gRNA4 for the α enhancer and FL gRNA1–gRNA3 or FL gRNA2–gRNA4 for the FL enhancer as described in Additional 
file 7. Untargeting control gRNA was used as control. For each gRNA couples, three independent homozygous clones were tested for Nr5a1 
expression by RT‑qPCR. Nr5a1 expression level was normalized to Gapdh. Data are the normalized mean ± SEM of six independent experiments. WT 
and Δ FL enh αT3–1 or Δ α enh αT3–1 clones were compared with ANOVA followed by Dunnett’s multiple comparison tests. Significant difference 
with WT: “c” p < 0.001. c The α enhancer is a functional enhancer of Nr5a1 in immature αT3–1 cells. The α enhancer was decommissioned in αT3–1 
cells using CRISPR/dCas9 fused with the lysine‑specific histone demethylase LSD1 coding sequence (dCas9–LSD1). The dCas9–LSD1 was targeted 
to the α enhancer genomic sequence using α gRNA1–gRNA3 or α gRNA2–gRNA4 gRNA couples. Untargeting control gRNA (Ctr gRNA) was 
used as control. The 25% highly transfected cells were retrieved using cytometry cell sorting and tested for Nr5a1 expression by RT‑qPCR. Nr5a1 
expression level was normalized to Gapdh. Data are the normalized mean ± SEM of three independent experiments and are compared to control 
untargeting gRNA using Student’s t test “b” p < 0.01. d The α enhancer interacts with Nr5a1 pituitary promoter in progenitor and immature cells. 
Top: Quantitative chromatin conformation capture (c) assay was carried out in αT1–1 and αT3–1 cells. Chimeric DNA fragments were detected 
using a fixed forward primer targeting the α enhancer and several forward primers targeting regions upstream, inside or downstream from the 1G 
pituitary promoter sequence as shown in the schematic diagram of Nr5a1 structure. Primers positions are indicated with red arrows for Ce (external 
to locus control region), FL (fetal Leydig enhancer), 1G (1G promoter), α (α enhancer) and Ci (internal to locus control region). Exons are indicated as 
dark bars, regulatory regions as green bars and α enhancer as a purple bar. Numbering is relative to 1A promoter TSS. Bottom: Histograms showing 
qPCR measurements of chimeric fragments in 3C library. Raw qPCR data were normalized to input and to Ci/α chimeric DNA used as a control of 
non‑specific ligation events. RP23 225F7 bacterial artificial chromosome (BAC) was used to create template enabling quantitative measurement 
of chimeric regions in the 3C library. Data are the mean ± SEM of four independent experiments and were analyzed with ANOVA followed by 
Dunnett’s multiple comparison tests. Significant difference with Ci/α: “b” p < 0.01; “c” p < 0.001, nd: not detected
(See figure on next page.)
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ERα controls cis‑regulatory activity of the α enhancer
In order to understand the mechanisms regulating α 
enhancer activity, genomic sequence conservation of the 
α enhancer peak-2 was analyzed across mammals (Fig. 4a). 
A 65-bp core sequence (mm9 chr2:38,560,050–38,560,114) 
is conserved including a 13-bp stretch showing more than 
60% of conservation. According to the cisBP online library 
[18], this element corresponds to a perfect ERE motif. No 
other conserved binding site could be identified in the rest 
of the core sequence (Additional file 2C).
In order to test the involvement of this 65-bp core 
sequence in the α enhancer cis-regulatory activity, trun-
cated sequences were tested by luciferase reporter assay 
in αT3–1 cells maintained in complete steroid-contain-
ing medium (Fig.  4b). The full-length α enhancer con-
struct (Pluc–α enh) displayed a significant cis-regulatory 
activity as compared to the minimal prolactin promoter 
(Pluc–Prl) used as control. The 65-bp core sequence 
(Pluc–α enh +65) showed similar activity as Pluc–α 
enh. Furthermore, deletion of the 65-bp core sequence 
(Pluc–α enh Δ65) or mutation of the potential ERE motif 
(Pluc–α enh MutERE) completely abolished cis-regula-
tory activity in αT3–1 cells. This demonstrates that the 
65-bp core conserved sequence is sufficient alone to drive 
α enhancer activity and that the ERE motif is crucial for 
this activity.
Both estrogen receptors α (ERα) and β (ERβ) bind to 
ERE motif. Esr1 and Esr2 mRNAs were quantified by RT-
qPCR (Fig.  4c). While Esr2 transcripts were undetect-
able, Esr1 was expressed in αT1–1 and αT3–1 cells, with 
a fivefold higher expression level in αT3–1 cells (Fig. 4c, 
p < 0.01). In mature LβT2 cells, Esr1 mRNA could hardly 
be detected.
ChIP using an anti-ERα antibody was then performed 
in αT1–1 and αT3–1 cells. ERα was strongly enriched 
on the α enhancer as compared to the control region in 
αT3–1 cells (Fig. 4d, p < 0.001). Binding of ERα to the α 
enhancer was also observed to a lesser extent in αT1–1 
cells (Additional file 4A, p < 0.01).
To further analyze the role of ERα in the regulation 
of α enhancer activity, Esr1 expression was knocked 
down using Esr1 SiRNA. Efficiency in ERα decrease was 
validated by western blot (Additional file  5A). Specific 
knockdown of ERα abolished α enhancer cis-regulatory 
activity in αT3–1 cells (Fig.  4e, p < 0.001). A significant 
decrease in α enhancer activity was also observed in 
αT1–1 cells (Additional file 4C).
In order to test ligand dependency, α enhancer activity 
was measured in the presence of 17β-estradiol (E2) or the 
widely used antagonist ICI 182,780 in the αT3–1 cells. 
While E2 dose-dependently activated α enhancer cis-
regulatory activity, ER inhibition led to a dose-dependent 
(See figure on next page.)
Fig. 4 ERα controls the cis‑regulatory activity of the α enhancer. a A 65‑bp core sequence of the α enhancer is conserved across mammalian 
genomes. The α enhancer genomic sequences of 31 mammalian species were retrieved on Ensembl Web site and aligned using Clustal Omega 
software. A 65‑bp core sequence displays clear conservation among the different species. In this core sequence, a perfect match with the canonical 
ERE‑binding site was observed (red bar and ERE‑binding motif ). b The ERE‑binding site in the 65‑bp core sequence is essential for α enhancer 
cis‑regulatory activity in immature αT3–1 cells. αT3–1 cells were transiently transfected in complete steroid‑containing culture medium with 
Pluc constructs containing either a minimal prolactin promoter (Pluc–Prl) used as control, a full‑length α enhancer (Pluc–α enh), a truncated α 
enhancer (Pluc–α enh Δ65, harboring a deletion of the 65‑bp core sequence), a reduced α enhancer (Pluc–α enh +65, containing only the 65‑bp 
core sequence) or a mutated α enhancer (Pluc–α enh MutERE with the following mutation in the ERE‑binding site: GAT CAA TGT GAT C). Prl minimal 
promoter is represented in dark followed by luciferase coding sequence shown in green, α enhancer is represented in blue, containing the 65‑bp 
core sequence in orange, and the ERE‑binding site in yellow. ERE mutation is indicated with asterisks. Relative luciferase activity was measured as 
indicated in “Materials and Methods.” Results were normalized to Pluc–Prl used as control and are the mean ± SEM of six independent experiments. 
Comparisons with control were performed with ANOVA followed by Dunnett’s multiple comparison tests. Significant difference with Pluc–Prl 
control: “c” p < 0.001. c Erα but not Erβ is expressed in immature αT3–1 cells. Total RNA from αT1–1, αT3–1 and LβT2 cells was extracted and reverse 
transcribed. The mRNA levels of Erα and Erβ were quantified as indicated in “Materials and Methods.” Results are normalized to Gapdh and are 
the mean ± SEM of four independent experiments. ANOVA followed by Bonferroni’s post hoc comparisons test was performed to compare Erα 
expression in the different cell lines. Significant difference: “a” p < 0.05 and “b” p < 0.01. Nd: not detected. d Endogenous ERα binds to the α enhancer 
chromatin in immature αT3–1 cells. ERα binding on α enhancer chromatin was investigated using ChIP assays in the αT3–1 cell line using the 
anti‑estrogen receptor alpha ChIP‑grade antibody (abcam ab32063). Quantitative PCR was performed using primers targeting the α enhancer 
sequence (α enh). Raw qPCR data were normalized to input. The final results were expressed as fold over the control region (Ctr region). Results 
are the mean ± SEM of four independent experiments. Significant difference with the control region using Student’s t‑test: “c” p < 0.001. e The 
cis‑regulatory activity of α enhancer is strictly dependent on Erα expression level. αT3–1 cells were transiently co‑transfected with control (Pluc–Prl) 
or full‑length α enhancer (Pluc–α enh) constructs and with scramble or Erα SiRNA. Relative luciferase activity was measured as indicated in “Materials 
and Methods.” Results were normalized to control Pluc–Prl plasmid and are the mean ± SEM of six independent experiments. Significant difference 
with the scramble SiRNA using Student’s t test “c” p < 0.001. f ERα agonist and antagonist modulate α enhancer cis‑regulatory activity. αT3–1 cells 
were transiently transfected with control (Pluc–Prl) or full‑length α enhancer (Pluc–α enh) constructs. Transfected cells were treated with either 
vehicle, E2 or ICI 182,780 at the indicated concentrations. Relative luciferase activity was measured as indicated in “Materials and Methods.” Results 
were normalized for control Pluc–Prl and are the mean ± SEM of six independent experiments. ANOVA followed by Dunnett’s multiple comparison 
tests was performed to compare drugs at different concentrations against vehicle. Significant difference with the vehicle: “c” p < 0.001
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repression (Fig.  4f ). A similar repression could be 
observed using the ERα-specific antagonist, MPP dihy-
drochloride (Additional file 5B).
To confirm α enhancer dependency to both ERα and 
E2, activities of the WT- and ERE-mutated α enhanc-
ers were assessed in the presence of E2 combined with 
ERα over-expression in LβT2 cells. We observed that α 
enhancer activity can be significantly induced by ERα 
over-expression alone (fold induction compared to basal 
of 19.7 ± 3.5, p < 0.001, Additional file  3B) and further 
increased by ERα over-expression combined with E2 
treatment (fold induction compared to basal of 65.1 ± 5.4, 
p < 0.001, Additional file 3B). Mutation of the ERE abol-
ished ERα and E2 effects on α enhancer cis-regulatory 
activity.
In order to investigate whether ERα is sufficient to 
activate the endogenous α enhancer in mature gonado-
trope cells, ERα was over-expressed in LβT2 cells and 
the α enhancer chromatin accessibility was assessed by 
ATAC-qPCR. We observed that over-expression of ERα 
is sufficient to significantly increase α enhancer chroma-
tin accessibility in mature gonadotropes (fold increase in 
chromatin accessibility of 2.2 ± 0.4, p < 0.01 Additional 
file 3C).
These results altogether demonstrate that the α 
enhancer is active only in immature gonadotrope cells 
and that this activity is regulated by ERα and E2.
ERα controls Nr5a1 expression through epigenetic 
regulation of the α enhancer and 1G promoter
To specifically inhibit ERα binding to the α enhancer, 
the ERE motif of α enhancer genomic sequence was 
excised using CRISPR/Cas9 in immature gonadotropes. 
Two αT3–1 clones (ΔERE) bearing homozygous dele-
tion of this ERE were retrieved. As expected, the deletion 
encompassed the ERE plus four additional bases at each 
side (Fig. 5a). ChIP assay showed that ERα enrichment on 
α enhancer was dramatically decreased in ΔERE clones 
as compared to WT (99% decrease p < 0.001) (Fig. 5b).
Nr5a1 expression level was then quantified in ΔERE 
clones. Compared to WT clones, Nr5a1 expression was 
decreased by 85% in ΔERE clones (Fig. 5c, p < 0.001).
To further characterize α enhancer regulation by ERα, 
epigenetic remodeling at the α enhancer and 1G pro-
moter was then investigated in ΔERE clones. DNase I 
hypersensitivity assay revealed that excision of ERE-
binding site led to a 90% decrease in α enhancer chro-
matin accessibility (Fig.  5d, p < 0.001). Comparison of 
histone mark decoration of α enhancer between ΔERE 
and WT clones revealed that deletion of ERE did not 
impact H3K4me1 deposition on the α enhancer (Fig. 5e). 
However, a 75% drop in H3K27ac enrichment could be 
observed (Fig. 5e, p < 0.001).
Binding of the P300 histone acetyltransferase to the α 
enhancer was then investigated by ChIP using anti-P300 
Fig. 5 ERα controls Nr5a1 expression through epigenetic regulation of the α enhancer. a Deletion of the α enhancer ERE‑binding site using CRISPR/
Cas9 in immature αT3–1 cells. Deletion of ERE genomic sequence in α enhancer was carried out in αT3–1 cells using CRISPR/Cas9 and a couple of 
specific gRNA flanking the ERE sequence. Untargeting gRNA was used as control. Two independent homozygous clones for both deletion and for 
control gRNA were sequenced. The genomic sequences of WT and deleted ERE (Δ ERE) αT3–1 clones are shown along with the ERE motif and the 
δERE–gRNA positions. b Deletion of the α enhancer ERE prevents ERα binding to the enhancer chromatin in immature αT3–1 cells. ERα binding on 
α enhancer chromatin was investigated using ChIP assays in WT and Δ ERE αT3–1 clones. Quantitative PCR was performed using primers targeting 
the α enhancer genomic sequence. Raw qPCR data were normalized to input. The final results were expressed as fold over the control region. 
Results are the mean ± SEM of six independent experiments. Significant difference with the control region was analyzed using Student’s t‑test: “c” 
p < 0.001. c An intact ERα‑binding site in the α enhancer is essential for Nr5a1 expression in immature αT3–1 cells. Nr5a1 expression in WT and Δ ERE 
αT3–1 cells was measured by RT‑qPCR. Nr5a1 expression level was normalized to Gapdh. Data are the normalized mean ± SEM of six independent 
experiments. Significant difference with the WT using Student’s t‑test: “c” p < 0.001. d Abolition of the ERα binding site in α enhancer leads to a 
strong reduction in the α enhancer chromatin accessibility in immature αT3–1 cells. The α enhancer chromatin accessibility was investigated using 
DNAse I hypersensitivity (DNase I HS) assay in WT and Δ ERE αT3–1 clones. Quantitative PCR was performed using primers targeting the α enhancer 
genomic sequence. Raw qPCR data were normalized to input. The final results were expressed as fold over the control region. Results are the 
mean ± SEM of four independent experiments. Significant difference with the WT using Student’s t‑test: “c” p < 0.001. e Abolition of the ERα‑binding 
site in the α enhancer prevents active chromatin marks deposition on the α enhancer and 1G promoter in immature αT3–1 cells. Monomethylation 
of Lys4 (H3K4me1), acetylation of Lys27 on histone H3 (H3K27ac) and trimethylation of Lys4 (H3K4me3) epigenetic modifications as well as 
binding of P300 and serine 5‑phosphorylated RNA polymerase II (S5P Pol II) to the α enhancer and/or 1G promoter sequences were studied 
using ChIP assays in WT and Δ ERE αT3–1 clones. Quantitative PCR was performed using sets of primers targeting the α enhancer or 1G promoter 
sequence. Raw qPCR data were normalized to input. The final results are expressed as fold over the control region. Results are the mean ± SEM 
of six independent experiments. Significant difference between WT and Δ ERE αT3–1 clones for each mark and each cis‑regulatory element was 
studied using Student’s t‑test: “b” p < 0.01; “c” p < 0.001. f Abolition of the ERα‑binding site in the α enhancer leads to CpG hypermethylation of the α 
enhancer chromatin in immature αT3–1 cells. Genomic DNA of WT and Δ ERE αT3–1 clones was extracted and bisulfited. The α enhancer‑bisulfited 
sequences were amplified and cloned. A minimum of nine clones per cell line was sequenced. Top: schematic representation of the α enhancer 
sequence with location of CpG (open‑circle lollipops) and of the ERE site. Below is indicated the state of CpG methylation for each cell line, 
methylated (black circles) or unmethylated (open circles)
(See figure on next page.)
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antibody. P300 was significantly enriched on the α 
enhancer in αT3–1 and to a lesser extent in αT1–1 cells 
(Additional file  4B, p < 0.01). Deletion of ERE led to an 
80% decrease in P300 recruitment in αT3–1 cells (Fig. 5e, 
p < 0.001). CpGs DNA methylation was analyzed in ΔERE 
compared with WT clones (Fig.  5g). Inhibition of ERα 
binding led to a hypermethylation of the α enhancer in 
immature gonadotropes.
Analysis of the 1G promoter epigenetics revealed that α 
enhancer repression did not affect H3K4me3 mark depo-
sition. It, however, decreased H3K27ac enrichment on 
the 1G promoter (60% decrease p < 0.01, Fig. 5e) without 
decreasing P300 recruitment. This decrease was associ-
ated with a decrease in serine 5-phosphorylated RNA 
polymerase II recruitment to the TSS (60% decrease 
p < 0.001, Fig. 5e).
Altogether, these results demonstrate that ERα binding 
to the α enhancer leads to epigenetic activation of the α 
enhancer and 1G promoter leading to Nr5a1 expression 
in immature gonadotropes.
Discussion
Gonadotrope differentiation is a stepwise process tak-
ing place during pituitary development. Gonadotrope 
lineage is characterized by the expression of Nr5a1, a 
mandatory TF for gonadotrope cell identity and matu-
ration [6]. However, the molecular mechanisms trigger-
ing Nr5a1 expression are still poorly understood. In the 
current study, we have analyzed the epigenetic mecha-
nisms implicated in this process. Using three cell lines 
recapitulating different stages of gonadotrope differentia-
tion and combining chromatin accessibility analyses with 
studies of epigenetic mark deposition and cis-regulatory 
activity, we re-evaluated the implication of previously 
described Nr5a1 cis-regulatory sequences and charac-
terized a yet unidentified enhancer element that initi-
ates Nr5a1 expression at the earliest step of gonadotrope 
specification.
Nr5a1 expression has been suggested to be under the 
control of the 1G promoter and β enhancer in differenti-
ating gonadotropes [8, 13]. Here, we confirmed that these 
two regulatory sequences are indeed activated in mature 
LβT2 cells. However, we showed that although the Nr5a1 
1G promoter is already active in immature gonadotropes, 
this is not true for the β enhancer that does not display 
any active chromatin marks or cis-regulatory activity 
at this differentiation stage. This demonstrates that, in 
immature gonadotropes, molecular mechanisms nec-
essary for β enhancer activity are not yet at work. The 
β enhancer is thus not the earliest enhancer triggering 
Nr5a1 expression during gonadotrope specification.
Previous experiments performed by Stallings et al. [9] 
demonstrated that genomic fragments encompassing the 
1G promoter are not sufficient to induce Nr5a1 expres-
sion in vivo in the pituitary. We thus decided to analyze 
chromatin accessibility in the Nr5a1 locus using our cel-
lular models of gonadotrope differentiation to search for 
new cis-regulatory elements. Among the different poten-
tial cis-regulatory elements showing chromatin acces-
sibility, one enhancer had already been characterized as 
a regulator of Nr5a1 expression in fetal Leydig cells [12]. 
We showed that this FL enhancer is active in immature 
and mature cells and repressed in progenitors. It, how-
ever, cannot be implicated in the initiation of Nr5a1 
expression as it is located inside the genomic fragments 
that were tested as negative by Stallings et al. [9]. Inter-
estingly, we identified a previously undescribed enhancer, 
the α enhancer, with an intriguing activation pattern: It 
is transiently and specifically activated at the immature 
stage in vitro. In order to investigate the activation of the 
α region in vivo, we studied chromatin accessibility in the 
Nr5a1 locus during mouse pituitary development. Inter-
estingly, the chromatin at the α region was only tran-
siently accessible at E13.5 corresponding to gonadotrope 
cell emergence and initiation of Nr5a1 expression. More-
over, this α enhancer displays bonafide active enhancer 
epigenetic mark decorations, with P300 recruitment, 
H3K27ac deposition and demethylated CpGs. Using both 
deletion and functional assays, we demonstrated that this 
enhancer is mandatory for Nr5a1 expression in immature 
gonadotropes, contrary to the FL and β enhancers. Alto-
gether, these data demonstrate that the α enhancer is the 
earliest activated cis-regulatory sequence of Nr5a1 gene, 
and as such, the earliest cis-regulatory sequence specifi-
cally activated during gonadotrope specification.
According to our work, Nr5a1 expression would be 
dynamically regulated by the sequential recruitment of 
two enhancers, the α enhancer during the early steps of 
lineage specification and then the β enhancer in mature 
gonadotropes. The FL enhancer, which is active during 
both stages, might act as a relay during this process. Sup-
porting this hypothesis, a recent work has demonstrated 
the involvement of such transiently activated enhancers 
during the motor neuron differentiation process [19].
Analysis of the sequence conservation of the α enhancer 
in mammals allowed us to identify an almost perfectly 
conserved ERE motif. We demonstrated that ERα binds 
to this ERE and that regulation of the α enhancer activ-
ity is estrogen dependent. During mouse embryogenesis, 
Esr1 is expressed in the developing pituitary from E12.5 
onwards [data from GenePaint.org (image C1253.3.4.B) 
and Additional file 6A]. However, fetal circulating estro-
gens are believed to be inactive. Yet, active estrogens can 
be locally produced either by desulfonation of circulating 
estrogens sulfate by the steroid sulfatase (STS) enzyme or 
by aromatization of circulating androgens by aromatase. 
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Genes encoding both enzymes are expressed in mouse 
and rat adult pituitaries [20–22]. Moreover, Sts tran-
scripts (but not of the aromatase coding gene Cyp19a1) 
are expressed in progenitor and immature gonadotrope 
cells (Additional file 6B), supporting the idea that differ-
entiating gonadotropes could locally produce the estro-
gens needed for α enhancer activation.
Interestingly, Nr5a1 expression has been shown to be 
regulated by estrogens in pituitary and testis [23, 24]. In 
addition, pituitary Nr5a1 expression can be affected by 
prenatal exposure to estrogenic endocrine-disrupting 
chemicals [25]. However, no functional ERE motif was 
found in Nr5a1 promoters. The α enhancer is thus a bon-
afide candidate to mediate estrogen regulation of Nr5a1 
expression though ERα recruitment.
Here, by precisely deleting ERE motif from the α 
enhancer genomic sequence using CRISPR/Cas9 
strategy, we successfully inhibited ERα binding. We 
observed that ERα binding is mandatory for Nr5a1 
expression in immature gonadotropes. We further 
demonstrated that ERα binding initiates epigenetic 
remodeling including P300 recruitment and subse-
quent H3K27ac deposition, maintaining both an open 
chromatin state and CpGs hypomethylation. Interest-
ingly, we observed that ERα binding to the α enhancer 
also remotely regulates the 1G promoter activity. Data 
obtained using quantitative 3C assay strongly suggest 
that promoter activation is mediated in part by chro-
matin looping. Recent evidence obtained from studies 
in several cellular models [26–28] indicates that ERα 
may regulate gene expression mainly through enhancer 
activation. It has also been shown in breast cancer cells 
that ERα binding to enhancers increases P300 recruit-
ment [29] and decreases DNA CpG methylation [30]. 
Our data demonstrate that ERα-dependent epigenetic 
regulation is also crucial during the earliest step of 
gonadotrope lineage specification.
Interestingly, we observed that ERα and P300 already 
bind to the α enhancer in progenitor cells and that 
CpGs around and inside the ERE motif remain hypo-
methylated. This suggests that ERα binding to the α 
enhancer in progenitors protects the ERE from de novo 
CpG methylation and allows enhancer pre-activation 
by increasing H3K27ac deposition. Very recently, ERα 
has been shown to be implicated in a biphasic recruit-
ment of P300 on enhancers [31]: Binding of ERα first 
leads to P300 recruitment and histone acetylation, 
promoting initial enhancer pre-activation; then, ERα 
co-activators are recruited to reinforce P300 binding, 
leading to enhancer maturation and full activation.
Over-expression of ERα combined to E2 treatment 
in the progenitor cell line is not sufficient to induce 
Nr5a1 expression (data not shown), suggesting that 
ERα is not able to activate the endogenous α enhancer 
in a repressed chromatin environment. This is con-
sistent with several works, showing that ERα requires 
pioneer TFs to bind to nucleosome-masked ERE sites 
[32]. Thus, these mandatory pioneer factors might not 
yet be expressed in the progenitor cells. Based on our 
study, we can hypothesize that the α enhancer is in a 
bivalent state in progenitor gonadotropes, silent yet 
prone to be activated by recruitment of ERα co-acti-
vators (Fig.  6). By contrast, over-expression of ERα is 
sufficient to re-activate the α enhancer in the mature 
gonadotropes. This suggests that in mature gon-
adotropes, the absence of ERα expression prevents α 
enhancer activation although the required co-activa-
tors or pioneer factors remain expressed at this stage. 
Moreover, as ERα is known to be expressed in adult 
gonadotropes, it would suggest that α enhancer might 
be recruited again in adulthood to regulate dynami-
cally Nr5a1 expression at important stages of repro-
ductive life.
Molecular mechanisms implicated in α enhancer 
activation and inhibition are in current investigation 
and should lead to the identification of new actors of 
gonadotrope lineage specification and function.
Conclusions
Gonadotrope cell specification is still not well under-
stood, and although key TFs and signaling pathways 
have been identified, the molecular events implicated 
in the very early steps of this lineage commitment 
remain elusive. Deciphering the dynamic of the regu-
latory enhancer network during gonadotrope specifi-
cation should significantly improve the understanding 
of this process. This knowledge is critical for efficient 
reprogramming of stem cells into mature gonadotropes 
that would have important therapeutic applications.
Methods
Cell cultures
The αT1–1, αT3–1 and LβT2 mouse gonadotrope cell 
lines (generously given by P. Mellon, University of Cali-
fornia, La Jolla, CA) were grown in monolayer cultures 
using high-glucose DMEM supplemented with 10% 
fetal bovine serum (FBS) and 0.2% penicillin/strepto-
mycin, at 37 °C with 5%  CO2.
Antibodies
Antibodies were purchased from Abcam: anti-
H3K4me1 ab8895; anti-H3K4me3 ab8580; anti-
H3K27ac ab4729; anti-PolII S-5-P ab5131; anti-ERα 
ab32063; anti-KAT3B ab19541, and from Santa Cruz: 
anti-GAPDH sc-25778.
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ATAC‑seq
Assay for transposase-accessible chromatin with 
high-throughput sequencing analysis was performed 
as described [33]. Briefly, 50,000 nuclei from αT1–1, 
αT3–1 and LβT2 cell lines were transposed using Illu-
mina Nextera Transposase. Library fragments were 
amplified using NEBnext PCR master mix and custom 
Nextera PCR primers. Sequencing was performed on 
a NextSeq 500 system at the ICM iGenSeq core facil-
ity from Paris. Three independent replicates were done 
for each line. Data analysis was performed according 
to Buenrostro et al. [33]. Briefly, ATAC-seq reads were 
mapped on mouse genome mm9 using Bowtie 2 [34] 
and peak calling was done using MACS2 [35]. Peaks 
were then tested for consistency among three inde-
pendent replicates, and data visualization was done 
using IVG software [36].
ATAC‑qPCR
Pregnant mice of the SWISS background at 12.5, 13.5 
and 14.5  days post coitum were purchased from Jan-
vier Labs. Mice were killed by cerebral dislocation and 
embryos retrieved and anesthetized in ice-cold PBS. 
Developing pituitaries were dissected under magnifica-
tion glasses. Six pituitaries from age-matched embryos 
were pooled and cells dispersed in high-glucose DMEM 
with 10% FBS supplemented with 1 mg/mL collagenase 
D and 40 U/mL DNase I for 30 min at 37 °C. Transpo-
sition, amplification and libraries were performed as 
described [33]. The experiment was performed three 
times independently in triplicates.
For each genomic region, specific enrichments were 
quantified by real-time PCR using LightCycler 480 
Instrument (Roche Diagnostics) and Takyon No ROX 
SYBR master mix (Eurogentec). Specific primers are 
described in Additional file 7. Raw qPCR data were nor-
malized to control region and to E12.5 stage of devel-
opment. The control region, already used in [14], is 
located at mm9 chr11:111,296,111–111,296,224 and 
is a region that displays neither enrichment for histone 
modifications, TF binding or chromatin accessibility 
so far on every tested tissues or cell types according to 
the ENCODE data. Change in chromatin accessibility 
between E12.5 and E13.5 or E12.5 and E14.5 embryonic 
stages was compared using a Mann–Whitney test.
Fig. 6 Schematic representation of the epigenetic mechanisms triggering Nr5a1 expression during the early steps of gonadotrope specification. 
In progenitors, the chromatin of the Nr5a1 locus is mainly in a repressed conformation: It is not yet accessible to TFs, DNA is methylated, and the 
gene is not expressed. While the promoter does not yet bear any epigenetic marks of activation, the α enhancer is already primed. Interestingly, 
the α enhancer is already looping on the pituitary 1G promoter and a limited chromatin accessibility of the α enhancer allows some binding of 
ligand‑activated ERα. ERα recruits only a limited amount of P300 on the enhancer, allowing a low level of histone acetylation. The α enhancer is 
thus in a bivalent state and the gene is on the verge of activation. In immature gonadotropes, CpGs are demethylated and chromatin accessibility 
on the α enhancer increased dramatically, as well as P300 recruitment and histone acetylation. These epigenetic modifications are ERα dependent. 
Activation of the α enhancer allows histone acetylation and recruitment of RNA Pol II on the pituitary 1G promoter and hence Nr5a1 transcription. 
The transition between α enhancer‑repressed and activated states is probably due in part to recruitment of ERα co‑activators that would be 
repressed or not yet expressed in progenitors
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DNase I hypersensitivity assay
DNase I-sensitive assay was performed as described 
[14]. Briefly, 50,000 nuclei were digested with 1 U RQ1 
DNase I (Promega) for 5  min at 32  °C. DNA was then 
extracted by proteinase K treatment and phenol/chloro-
form extraction. DNA fragments were segregated by size 
by centrifugation for 24  h at 25,000  g on a 9% sucrose 
cushion. A 500-µL fraction representing fragments of 
less than 1000  bp was collected at the top of the gradi-
ent and precipitated. The experiment was performed in 
triplicates on two independent clones. The α enhancer 
sequence enrichment in the purified DNA fractions was 
quantified by real-time PCR. Primers are described in 
Additional file 7.
Chromatin immunoprecipitation
ChIP experiments were performed as described [14]. 
Briefly, 20 million cells were cross-linked with 1% for-
maldehyde for 10 min (or 30 min for P300 ChIP) at 37 °C, 
and then, formaldehyde was quenched by adding glycine 
(125 mM final). After nuclei extraction and lysis, chroma-
tin was sheared by five 25-s rounds of sonication at 50% 
setting with a Bioblock Scientific Vibra-Cell sonicator. 
About 50 µg of chromatin for histone chromatin epigenetic 
marks and 100 µg for TFs along with 5 µg of antibodies per 
immunoprecipitation were combined. Immunoprecipita-
tion was carried out at 4 °C overnight using Dynabeads™ 
Protein G (Invitrogen, ThermoFisher Scientific). After 
extensive washings and elution, chromatin cross-linking 
was reverted by heat and DNA purified using phenol/chlo-
roform extraction and precipitation. Each ChIP experi-
ment was performed at least six times independently.
For each genomic region, specific enrichments were 
quantified by real-time PCR. Specific primers are 
described in Additional file 7. Raw qPCR data were nor-
malized to chromatin inputs and control region and were 
then compared using ANOVA followed by Dunnett’s 
multiple comparison, performed independently for each 
cell line and each histone marks or TF after checking for 
normal distribution using Kolmogorov–Smirnov test.
Luciferase reporter assay
Cloning of the cis-regulatory region: Genomic regions 
encompassing each potential cis-regulatory element were 
amplified from mouse DNA and cloned upstream from a 
minimal prolactin promoter (Prl) in the pGL3-basic vec-
tor (Promega) as previously described [37]. Truncated 
regions were obtained by PCR or fusion PCR. Primers 
for amplifications and truncations are described in Addi-
tional file 7.
Cell transfection: Briefly, 50,000 cells were transiently 
transfected in 96-well plates with 100  ng/well of pGL3 
plasmids along with 5  ng/well of pRL-SV Renilla plas-
mid as an internal control for normalization, using 
 Lipofectamine® 2000 (ThermoFisher Scientific) accord-
ing to the manufacturer’s protocol. When indicated, cells 
were co-transfected with either Dharmacon ON-TAR-
GETplus non-targeting control SiRNAs (D-001810-01-
05) or ON-TARGETplus Esr1 SiRNA (LQ-058688-01) at 
10  pmol/well. When indicated, 24  h after transfection, 
cells were treated with either vehicle, E2, ICI 182,780 
or MPP dihydrochloride at the indicated concentra-
tions in complete steroid-containing or steroid-deprived 
medium. At 48  h after transfection, firefly and Renilla 
luciferase activities were measured using the Dual-Lucif-
erase Reporter Assay System (Promega) according to the 
manufacturer’s instructions. Each experiment was per-
formed six times independently in quadruplicates. Data 
were normalized to Renilla and control Pluc–Prl plas-
mid level for each condition. Normal distribution was 
checked using Kolmogorov–Smirnov test, and ANOVA 
followed by Dunnett’s multiple comparison tests was 
performed independently for each cell line and each 
condition.
Bisulfite conversion of genomic DNA and sequencing
DNA methylation was performed as described previously 
[15]. Bisulfited fragments were cloned into pGEM-T Easy 
vector (Promega). At least five clones per cell line were 
selected and sequenced to determine the state of CpG 
methylation. Primers used for bisulfited DNA amplifica-
tion are listed in Additional file 7.
Quantitative chromatin conformation capture
3C experiments were conducted as described [38]. 
Briefly, 10 million cells were cross-linked with 2% for-
maldehyde for 10 min at 25  °C, and formaldehyde was 
then quenched by adding glycine (125 mM final). After 
nuclei extraction, restriction using 750 U of HindIII 
was carried out overnight at 37  °C under gentle agita-
tion. After enzyme inactivation, in nucleus ligations 
were performed overnight at 16  °C. Chromatin cross-
linking was reverted by heat and DNA purified using 
phenol/chloroform extraction and precipitation. A 
BAC library containing all possible chimeric fragments 
in equal amount was generated as followed: About 
10  µg of RP23 225F7 Nr5a1 BAC (gift from Dr CT. 
Gross, EMBL, Italy) was restricted with HindIII, reli-
gated and used as a control PCR template. For each cell 
line, four independent experiments were performed 
in triplicates. Chimeric DNA fragments quantification 
was carried out using specific primers encompassing 
the HindIII restriction sites on both the α enhancer and 
tested regions by qPCR. The BAC library was used as 
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a standard for unbiased concentration estimation. Data 
were normalized to the α enhancer and internal control 
Ci chimeric fragment level and analyzed using Kolmog-
orov–Smirnov test and ANOVA followed by Dunnett’s 
multiple comparison tests.
CRISPR/Cas9 deletions and dCas9–LSD1 enhancer 
inhibition
pLV hUbC-Cas9-T2A-GFP (#53190), pLV hUbC-dCas9-
T2A-GFP (#53191) and pSPgRNA (#47108) plasmids 
[39] were purchased from Addgene. The Lsd1 cod-
ing sequence was amplified from pET15B-hLSD1 (gift 
from Dr. Y. Shi, Harvard Medical School, Boston, USA) 
and cloned in frame of the C terminus of dCas9 in the 
pLV hUbC-dCas9-T2A-GFP plasmid. The specific guide 
RNAs were designed using CCTop online tool [40] and 
cloned in pSPgRNA plasmid.
About 5 million αT3–1 cells were electroporated with 
the Cas9 expression vector and sgRNA plasmids at a ratio 
of 1.5:8.5  µg using a  Neon® Transfection System (Invit-
rogen) according to the manufacturer’s protocol (two 
pulses at 1500 mV for 15 ms). The empty pSPgRNA was 
used as control. At 48 h post-transfection, GFP-positive 
cells were sorted using the FACS Aria II on the PIC2 
facility of the Unit of Functional and Adaptive Biology.
For enhancer deletion studies, sorted cells were plated 
at low density and expanded. Single colonies were tested 
for deletion by PCR. A minimum of two independent 
homozygous clones were selected.
For enhancer decommissioning assay, sorted cells 
were directly processed for RNA extractions. These 
experiments were performed in triplicates, three times 
independently.
RNA extraction and mRNA quantification
Total RNA was isolated from cells using Trizol reagent 
according to the manufacturer’s protocol. RNAs (1  µg) 
were reverse transcribed with SuperScript II reverse 
transcriptase (Invitrogen) using random primers accord-
ing to the manufacturer’s instructions. Specific prim-
ers for qPCR quantification are described in Additional 
file 7. For each cell line, experiments were conducted four 
times independently in triplicates.
Protein extraction and western blot
Cellular proteins were extracted in Laemmli buffer and 
separated on a 10% SDS–PAGE. After transfer, nitrocel-
lulose membranes were incubated with anti-ERα (1:1000) 
or anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; 1:3000) antibody in Tris-buffered saline con-
taining 0.01% Tween 20 (TBS-T) supplemented with 5% 
milk overnight at 4 °C. After extensive washing, blots were 
incubated with a horseradish peroxidase-conjugated sec-
ondary antibody (GE healthcare #NA934V) in TBS-T/5% 
milk for 60 min at a room temperature and then washed. 
Immunodetection was performed using an enhanced 
chemiluminescence detection system (GE Healthcare).
Immunohistochemistry staining of ERα
E12.5, E13.5 and E14.5 mouse embryos were proceeded 
for paraffin-embedded classical histology and were sec-
tioned into 5-µm thickness. The sections were mounted 
on positively charged slides. The slides were depar-
affinized using Histolemon and re-hydrated. Epitopes 
retrieval was performed by incubation in 0.05% citra-
conic anhydride buffer (pH 7.4) at 100   °C for 15 min. 
Endogenous peroxidase was inhibited by incubation 
in 30%  H2O2 for 20  min. Endogenous biotin molecules 
were blocked with endogenous avidin/biotin blocking 
kit (ab64212), and non-specific binding was blocked by 
incubation with 10% goat serum diluted in PBS for 1 h. 
Subsequently, the sections were incubated overnight in 
a humid chamber at RT 1  h with ERα antibody (1/200; 
ab32063 abcam). Sections were extensively washed and 
incubated for 1 h with the biotinylated anti-rabbit IgG 
secondary antibody (1/500; ab97049 abcam). Sections 
were extensively washed and incubated 1  h with HRP-
conjugated streptavidin (1/1000; ab7403 abcam). The 
sections were finally treated with diaminobenzidine in 
the dark, washed, then rapidly counterstained with May-
er’s Hemalun and mounted in Eukitt medium.
Additional files
Additional file 1. Differential chromatin accessibility in gonadotropes 
expressed gene locus during specification. Chromatin accessibility was 
investigated by assay for transposase‑accessible chromatin with high‑
throughput sequencing (ATAC‑seq) in αT1–1, αT3–1 and LβT2 gonado‑
trope cell lines. ATAC‑seq tracks are shown for Isl1, Cga, Gnrhr and Lhb 
loci. Accessible chromatin regions identified from ATAC‑seq results are 
shown for each cell line under each track (respectively, in gray, blue and 
yellow). In the last lane is shown genes structure (exon in blue boxes) with 
proximal promoters (red boxes).
Additional file 2. A The 3′ peak in Nr5a1 α enhancer is inactive, while 
the 5′ peak displays differential cis‑regulatory activity depending on 
gonadotrope differentiation stage. αT1–1, αT3–1 and LβT2 cells were 
transiently transfected with 5′ and 3′ peaks of the α region cloned in a 
pGL3b luciferase reporter system containing a minimal prolactin promoter 
(Pluc–Prl). Relative luciferase activity was measured as indicated in “Materi‑
als and Methods.” ANOVA followed by Dunnett’s multiple comparison tests 
was performed independently for each cell line. Results are normalized 
to control Pluc–Prl plasmid and are the mean ± SEM of six independent 
experiments. Significant difference with the control construct: “c” p < 0.001. 
B Deletion of the α enhancer using CRISPR/Cas9 in immature αT3–1 cells. 
Genomic sequences of the α enhancer of WT and α gRNA1–gRNA3‑ or 
α gRNA2–gRNA4‑deleted αT3–1 clones were amplified and sequenced. 
The aligned genomic sequences of WT and deleted clones are shown 
along with the δERE–gRNA positions. C Schematic representation of the α 
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enhancer predicted transcription factor binding sites for 31 mammals 
species. The α enhancer 65‑bp core sequences for 31 mammalian 
species were analyzed using cisBP online library (18). Predicted TFBS are 
represented according to the position. Only the conserved DNA based 
is indicated.
Additional file 3. A The α enhancer is an inactive enhancer of Nr5a1 
in mature LβT2 cells. The α and the β enhancers were decommis‑
sioned in LβT2 cells using CRISPR/dCas9 fused with the lysine‑specific 
histone demethylase LSD1 coding sequence (dCas9–LSD1). The 
dCas9–LSD1 was targeted to the α enhancer genomic sequence using 
the α gRNA1–gRNA3 gRNA couple and to the β enhancer genomic 
sequence using the β gRNA1–gRNA3 gRNA couple. Untargeting 
control gRNA (Ctr gRNA) was used as control. The 25% highly trans‑
fected cells were retrieved using cytometry cell sorting and tested for 
Nr5a1 expression by RT‑qPCR. Nr5a1 expression level was normalized 
to Gapdh. Data are the normalized mean ± SEM of three independ‑
ent experiments and are compared to cells transfected with control 
untargeting gRNA using Student’s t test “b” p < 0.01. B The cis‑regulatory 
activity of the α enhancer is strictly dependent on Erα expression 
level and E2 in mature gonadotrope cells. LβT2 cells were transiently 
transfected with control (Pluc–Prl), full‑length α enhancer (Pluc–α enh) 
or the mutated α enhancer (Pluc–α enh MutERE) constructs along with 
psg5 ERα expression plasmid or psg5 control plasmid in a steroid‑
deprived medium. Transfected cells were treated with either vehicle 
or E2 at 1 nM. Relative luciferase activity was measured as indicated 
in “Materials and Methods.” Results are normalized to corresponding 
Pluc–Prl plasmid and are the mean ± SEM of six independent experi‑
ments. ANOVA followed by Dunnett’s multiple comparison tests was 
performed: significant difference with the vehicle condition (gray bar): 
“c” p < 0.001. C ERα expression is sufficient to activate endogenous α 
enhancer in mature gonadotrope cells. LβT2 cells were transiently 
co‑transfected with control (psg5), or psg5‑ERα expression plasmid 
and pEGFP‑N1. An ATAC assay followed by real‑time PCR quantification 
(ATAC‑qPCR) was performed on the 25% highly transfected GFP cells 
retrieved using cytometry cell sorting. Quantitative PCR was performed 
using primers targeting Nr5a1 α and β enhancers. Raw qPCR data were 
normalized to control region. Results are the mean ± SEM of three 
independent experiments. Significant difference with the control psg5 
transfected condition “b” p < 0.01.
Additional file 4. A ERα binds to the α enhancer in progenitor αT1–1 
gonadotropes. ERα binding on the α enhancer chromatin was investi‑
gated using ChIP assays in αT1–1 cells. Quantitative PCR was performed 
using primers targeting the α enhancer genomic sequence. Raw 
qPCR data were normalized to input. The final results were expressed 
as fold over the control region. Results are the mean ± SEM of three 
independent experiments in triplicates. Significant difference with the 
control region was analyzed using Student’s t‑test: “b” p < 0.01. B P300 
binds to α enhancer in progenitor αT1–1 gonadotropes. P300 binding 
on the α enhancer chromatin was investigated using ChIP assays in 
αT1–1 cells. Quantitative PCR was performed using primers targeting 
the α enhancer genomic sequence. Raw qPCR data were normalized to 
input. The final results were expressed as fold over the control region. 
Results are the mean ± SEM of three independent experiments in 
triplicates. Significant difference with the control region was analyzed 
using Student’s t‑test: “c” p < 0.001. C The cis‑regulatory activity of the 
α enhancer is dependent on Erα expression level in progenitor αT1–1 
gonadotropes. αT1–1 cells were transiently co‑transfected with control 
(Pluc–Prl) or full‑length α enhancer (Pluc–α enh) Pluc constructs and 
with scramble or Erα SiRNA. Relative luciferase activity was measured 
as indicated in “Materials and Methods.” Results were normalized to 
control Pluc–Prl plasmid and are the mean ± SEM of three independent 
experiments in quadruplicates. Significant difference with the scramble 
SiRNA using Student’s t‑test “c” p < 0.001.
Additional file 5. A Knockdown efficiency of ERα SiRNA in αT3–1 cells. 
αT3–1 cells were transiently transfected in duplicates with scramble or 
Erα SiRNA. Proteins were extracted 48 h later. Western blots for ERα and 
GAPDH immunodetection were performed as indicated in “Materi‑
als and Methods.” Top: ERα immunodetection: The 66‑kDa and the 
36‑kDa isoforms are expressed in αT3–1 cells. Erα SiRNA allows efficient 
knockdown of both isoforms. Bottom: GAPDH immunodetection for 
normalization. B ERα specific antagonist MPP dihydrochloride modulates 
α enhancer cis‑regulatory activity. αT3–1 cells were transiently transfected 
with control (Prl) or full‑length α enhancer (α enh) Pluc constructs. Trans‑
fected cells were treated with either vehicle or MPP dihydrochloride at 
the indicated concentrations. Relative luciferase activity was measured as 
indicated in “Materials and Methods.” Results were normalized for control 
Pluc–Prl–luc and are the mean ± SEM of six independent experiments in 
quadruplicates. ANOVA followed by Dunnett’s multiple comparison tests 
was performed to compare drugs at different concentrations against 
vehicle condition. Significant difference with the vehicle: “c” p < 0.001.
Additional file 6. A ERα expression in the developing mouse pituitary. 
ERα immunohistochemistry analysis of pituitaries of embryos at E12.5, 
E13.5 and E14.5. ERα is expressed at E12.5, E13.5 and E14.5 in the develop‑
ing pituitary. Negative controls with no ERα antibodies were performed 
and yielded no signal (data not shown). Magnification: 600X. B Cyp19a1 
and Sts expression during gonadotrope cell differentiation. Cyp19a1 and 
Sts expressions in αT1–1, αT3–1 and LβT2 cells were measured by RT‑
qPCR. Expression level was normalized to Gapdh. Data are the normalized 
mean ± SEM of three independent experiments. Significant difference 
with water: “c” p < 0.001. Nd: not detected.
Additional file 7. Primers used in this study.
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